In vivo , micro-morphological vascular changes induced by topical brimonidine studied by Dynamic optical coherence tomography-Reference-Cited by-同舟云学术

In vivo , micro-morphological vascular changes induced by topical brimonidine studied by Dynamic optical coherence tomography

Published:2016-02-25 Issue:6 Volume:30 Page:974-979
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Themstrup L.¹,Ciardo S.²,Manfredi M.³,Ulrich M.⁴,Pellacani G.²,Welzel J.⁵,Jemec G.B.E.¹

Affiliation:

1. Department of Dermatology; Roskilde Hospital; University of Copenhagen; Roskilde Denmark

2. Department of Dermatology; University of Modena and Reggio Emilia; Modena Italy

3. Department of Engineering “Enzo Ferrari”; University of Modena and Reggio Emilia; Modena Italy

4. CMB/Collegium Medicum Berlin; Berlin Germany

5. Department of Dermatology and Allergology; General Hospital Augsburg; Augsburg Germany

Funder

Competitiveness and Innovation Framework Programme

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.13596/fullpdf

Reference18 articles.

1. Vasoconstriction and anti-inflammatory properties of the selective alpha-adrenergic receptor agonist brimonidine;Piwnica;J Dermatol Sci,2014

2. The Role of Topical Brimonidine Tartrate Gel as a Novel Therapeutic Option for Persistent Facial Erythema Associated with Rosacea;Johnson;Dermatol Ther,2015

3. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies;Fowler;Br J Dermatol,2012

4. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study;Moore;J Drugs Dermatol,2014

5. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies;Fowler;J Drugs Dermatol,2013

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dynamic optical coherence tomography for imaging acute wound healing;International Wound Journal;2024-08

2. Mapping cutaneous field carcinogenesis of nonmelanoma skin cancer using mesoscopic imaging of pro‐inflammation cues;Experimental Dermatology;2024-04

3. The role and safety of UVA and UVB in UV-induced skin erythema;Frontiers in Medicine;2023-06-27

4. Topical brimonidine for the management of facial erythema in rosacea: a histological, histometric, and immunohistochemical study;International Journal of Dermatology;2023-05-22

5. A multimodal, comprehensive characterization of a cutaneous wound model in healthy volunteers;Experimental Dermatology;2023-04-13